Katherine Prescott

Kate has over a decade of experience in research commercialisation, venture building, and strategic leadership across healthcare, AI, and impact-driven ventures. Her work focuses on translating research into real-world applications that deliver meaningful health and economic outcomes. She is leading programme delivery for the Oxford–GSK partnership, advancing AI and biostatistics research across clinical trial optimisation, uncertainty in large language models, causal reasoning, multi-omics, and intelligent data gathering. She was part of the founding team at Motilent, contributing to the development and commercialisation of CE-marked, FDA-approved imaging technologies now used globally, and continues to serve as a Non-Executive Director.

Previously, Kate was an Investment Principal at Mahdavi Investments, leading early-stage investments in deep tech and AI and supporting ventures through to successful exits. She led the FLIGHT and SIGHT programmes at Brighton and Sussex Medical School, working with global health partners across medical research valorisation, business development, and technology transfer. In addition, she undertakes advisory engagements with research-led organisations and spin-outs focused on research commercialisation and venture formation.